An investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, showing unprecedented weight loss in early clinical trials.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Retatrutide is a synthetic peptide developed by Eli Lilly and Company that simultaneously activates three distinct G protein-coupled receptors involved in energy metabolism: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple agonism earned retatrutide the informal designation of “triple G” agonist and established it as the first-in-class molecule of its type to reach human clinical trials with rigorous efficacy data.
The peptide was rationally designed starting from a GIP analog backbone — the same starting point used for tirzepatide — with additional modifications to restore and optimize potency at the glucagon receptor. Glucagon was historically viewed as an adversarial hormone in the context of metabolic disease, primarily because it stimulates hepatic glucose production and opposes insulin’s glucose-lowering effects. The paradigm shift underpinning retatrutide’s design is that glucagon receptor activation in the liver and adipose tissue can drive fat oxidation, increase energy expenditure through thermogenesis, and reduce hepatic lipid accumulation — provided these effects are appropriately balanced by simultaneous incretin receptor activation to prevent the glucose-raising consequences of unopposed glucagonergic signaling.
Structurally, retatrutide is a 24-amino acid peptide with a C20 fatty acid moiety enabling extended half-life through albumin binding, supporting once-weekly subcutaneous dosing analogous to tirzepatide. The specific amino acid substitutions that confer glucagon receptor activity while maintaining high GIP and GLP-1 receptor affinities represent a significant medicinal chemistry achievement, as the three receptor binding domains have overlapping but distinct structural requirements.
As of early 2026, retatrutide remains an investigational compound without regulatory approval in any jurisdiction. Its clinical development program has advanced through Phase 2 trials, with the pivotal Phase 3 program in obesity and metabolic disease expected to be fully underway. The most widely cited Phase 2 data were published in the New England Journal of Medicine in 2023, reporting 24.2% mean body weight loss at 48 weeks in participants receiving the highest studied dose — results that surpassed the landmark SURMOUNT-1 tirzepatide data and attracted considerable attention from the research and clinical communities alike.
Researchers interested in exploring triple agonist pharmacology can cross-reference related compounds using the peptide database for receptor binding profiles and structural comparisons.
Retatrutide’s pharmacological activity begins when it binds simultaneously to GLP-1R, GIPR, and GCGR, triggering intracellular signaling cascades through Gs protein coupling at all three receptors. Each receptor activates adenylyl cyclase, raising intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA), but the downstream consequences vary markedly by tissue and cell type. In pancreatic beta cells, all three receptors converge on the same insulin secretagogue machinery, producing additive glucose-stimulated insulin release. In alpha cells, GLP-1R activation suppresses glucagon secretion while GCGR agonism directly stimulates alpha cell cAMP — an apparent paradox that results in a pharmacologically titrated net alpha-cell effect that is predominantly suppressive at the doses used clinically, thereby avoiding net hyperglycemia despite the presence of glucagon agonism.
The peptide’s affinities at the three receptors were deliberately tuned during medicinal chemistry optimization. In cell-based assays, retatrutide displays high potency at all three receptors, with EC50 values in the low nanomolar range, though the relative potency ratios differ slightly from those of native glucagon, GIP, and GLP-1. The fatty acid moiety responsible for albumin binding also subtly modulates receptor engagement kinetics, favoring sustained, low-level receptor activation over the sharp peaks and troughs associated with shorter-acting peptides.
The glucagon receptor component of retatrutide’s mechanism is what most clearly distinguishes it from dual GIP/GLP-1 agonists and gives it its potentially superior weight-loss efficacy. In brown adipose tissue, GCGR activation increases the expression of uncoupling protein 1 (UCP1), which dissipates the mitochondrial proton gradient as heat rather than ATP, increasing basal metabolic rate. Rodent studies using selective GCGR agonists and glucagon infusion studies in healthy humans both confirm this thermogenic effect, with increases in oxygen consumption of 5–15% documented in various experimental settings.
In the liver, GCGR activation upregulates peroxisome proliferator-activated receptor alpha (PPARα), a master transcription factor for hepatic fatty acid oxidation gene expression. This increases the rate at which the liver oxidizes fatty acids imported from adipose tissue and reduces the availability of fatty acid substrates for VLDL triglyceride synthesis. The result is a dual benefit: less hepatic fat accumulation and lower circulating triglycerides. In skeletal muscle, glucagon receptor signaling appears to promote substrate switching toward fat oxidation over glucose, which may contribute to improved insulin sensitivity through a mechanism analogous to the “lipid hypothesis” of insulin resistance. Retatrutide’s concurrent GIP and GLP-1 receptor activation prevents the hyperglycemia that would result from isolated glucagon receptor stimulation by ensuring that insulin secretion and hepatic insulin signaling are simultaneously upregulated.
All three of retatrutide’s target receptors are expressed in the central nervous system, though their relative contributions to appetite regulation are differentially understood. The GLP-1 receptor’s role in hypothalamic and brainstem satiety circuits is the best-characterized: GLP-1R agonism reduces meal size, increases inter-meal interval, and decreases hedonic eating through effects on reward-related circuits in the nucleus accumbens and prefrontal cortex. GIPR is expressed in hypothalamic neurons including those of the arcuate nucleus, where it may modulate POMC and AgRP neuronal activity in ways that complement GLP-1R-mediated anorexia.
The glucagon receptor is expressed in several hypothalamic regions and may contribute to appetite suppression through mechanisms independent of the well-defined GLP-1 pathway, though the relative magnitude of this central GCGR contribution to retatrutide’s anorectic effects compared with peripheral GCGR-driven thermogenesis is not yet fully quantified. Functional MRI studies in participants treated with triple agonists are beginning to map the brain regions where combined receptor activation reduces food-cue reactivity and homeostatic hunger signals, data that will be important for understanding why some individuals respond more robustly than others. The AI coach can help interpret emerging mechanistic research in this rapidly evolving area.
The landmark Phase 2 retatrutide obesity trial, published in the New England Journal of Medicine in June 2023, enrolled 338 adults with a BMI of 30 or greater (or 27–30 with at least one weight-related comorbidity) who did not have type 2 diabetes. Participants were randomized to one of six retatrutide dose regimens — spanning 1 mg, 4 mg, 8 mg, or 12 mg weekly with varying escalation schedules — or to placebo for 48 weeks.
At 48 weeks, mean percentage body weight changes were -8.7% (1 mg), -17.3% (4 mg), -22.8% (8 mg), and -24.2% (12 mg with 4 mg escalation start), compared with -2.1% on placebo. In the 12 mg highest-dose group, 26% of participants achieved at least 30% total body weight loss — a threshold that had been described as effectively impossible with non-surgical intervention prior to this era. Nearly all participants in the 8 mg and 12 mg groups achieved at least 5% weight loss, demonstrating remarkably broad efficacy across the enrolled population. The weight loss trajectories had not fully plateaued at 48 weeks in the highest dose groups, suggesting that longer treatment would yield additional reductions. Adverse events were predominantly gastrointestinal and consistent with the incretin agonist class profile, with no new safety signals identified.
A separate Phase 2 trial enrolled adults with type 2 diabetes at doses ranging from 0.5 mg to 12 mg weekly. This population was particularly informative regarding the interplay between glucagon receptor agonism and glycemic control. Despite the theoretical concern that glucagon agonism would raise blood glucose, the net glycemic effect was strongly favorable: HbA1c fell by 1.2–2.2 percentage points from baselines of approximately 8.0–8.3% across active dose groups, consistent with data from pure GLP-1R agonists and tirzepatide, and a substantial proportion of participants achieved HbA1c below 7.0%.
Importantly, the incidence of hypoglycemia was low across all dose groups despite the magnitude of HbA1c reduction, consistent with the glucose-dependence of GLP-1R and GIPR-mediated insulin secretion acting as a built-in safety mechanism. Body weight reductions in this diabetic cohort were somewhat attenuated compared to the non-diabetic obesity trial, consistent with a pattern seen across the GLP-1R agonist class where the presence of diabetes modestly reduces the pharmacological weight loss achievable. The Phase 3 diabetes program was expected to include both glycemic control and cardiovascular outcome endpoints, following the regulatory precedent established by the SURPASS program for tirzepatide.
A key secondary finding from the Phase 2 obesity trial was a dramatic reduction in MRI-measured hepatic fat fraction. In participants with elevated baseline liver fat (defined as MRI-PDFF above 5%), retatrutide reduced liver fat fraction by an average of approximately 81% in the highest dose group — from a mean of about 16% at baseline to below 3% at week 48, representing a near-complete normalization of liver fat in the majority of affected participants. This magnitude of hepatic fat reduction substantially exceeds what has been reported for tirzepatide or semaglutide in comparable non-biopsy studies.
The mechanistic basis for this remarkable hepatic response likely involves all three receptor pathways: GLP-1R reduces de novo lipogenesis and improves hepatic insulin sensitivity, GIP receptor activation improves adipose tissue function and reduces the flux of non-esterified fatty acids to the liver, and glucagon receptor activation directly drives hepatic fatty acid beta-oxidation. Researchers speculate that the combination creates a “perfect storm” of pro-resolution signals for liver fat that individually effective drugs cannot match. Liver biopsy substudies within Phase 3 trials will determine whether this translates to histological MASH resolution and fibrosis regression, the regulatory endpoints required for an approved MASH indication.
Beyond weight and liver fat, Phase 2 participants showed a consistent and broad improvement in cardiometabolic risk factors. Triglycerides fell by 26–42% from baseline across dose groups — reductions substantially larger than those typically seen with tirzepatide at comparable doses — consistent with the glucagon receptor-driven suppression of hepatic VLDL production. Systolic blood pressure decreased by 5–10 mmHg, with the magnitude appearing somewhat greater in participants with higher baseline blood pressure. HDL-cholesterol increased modestly (approximately 5–8%), and LDL-cholesterol showed variable responses, an area of ongoing investigation since glucagon receptor activation can increase hepatic LDL receptor expression but also may influence PCSK9 pathway activity.
Markers of systemic inflammation, including high-sensitivity C-reactive protein (hsCRP), declined substantially in parallel with weight loss, consistent with the anti-inflammatory consequences of adipose tissue reduction and improved metabolic homeostasis. Uric acid levels, a marker associated with gout risk and cardiovascular disease, also declined, possibly related to improved renal urate clearance secondary to blood pressure normalization and reduced visceral adiposity-driven xanthine oxidase activity. The cardiovascular outcomes program for retatrutide was in planning stages as of early 2026.
Metabolic syndrome — defined by the constellation of abdominal obesity, elevated fasting glucose, elevated triglycerides, low HDL-cholesterol, and elevated blood pressure — was highly prevalent in the Phase 2 trial populations. Retatrutide’s simultaneous effects on all five diagnostic components of metabolic syndrome make it a compelling research tool for investigating whether pharmacological resolution of the syndrome produces the expected downstream reductions in cardiovascular and diabetes risk.
Post-hoc analyses of Phase 2 participants showed that retatrutide at 8 mg and 12 mg weekly effectively reversed metabolic syndrome criteria in the majority of participants who met diagnostic thresholds at baseline. The proportion of participants meeting ATP-III metabolic syndrome criteria fell from approximately 70% at baseline to under 20% by week 48 in the highest dose groups. These are remarkable findings, though they require confirmation in larger Phase 3 cohorts with longer follow-up and formal prospective metabolic syndrome resolution as a secondary endpoint. The degree to which benefits are maintained after treatment cessation is also a critical unanswered question, given the rebound dynamics demonstrated in tirzepatide withdrawal studies.
The Phase 2 retatrutide trials tested doses of 1 mg, 4 mg, 8 mg, and 12 mg weekly, with the 8 mg and 12 mg doses demonstrating the most robust efficacy. Two escalation strategies were tested for the 12 mg group: one beginning at 2 mg and escalating every four weeks, and another beginning at 4 mg. The 4 mg starting escalation produced slightly lower early gastrointestinal side effects while achieving equivalent peak efficacy at 48 weeks. The 1 mg dose produced modest weight loss and minimal glycemic improvement, suggesting this is near the lower threshold of meaningful pharmacological activity.
Phase 3 trial design details were not fully published as of early 2026, but based on Phase 2 findings and standard Eli Lilly development approaches, Phase 3 protocols likely involve doses of 4 mg, 8 mg, and 12 mg with gradual escalation starting at 2 mg. The dose-response relationship is steep between 1 mg and 8 mg and appears to plateau somewhat between 8 mg and 12 mg in terms of efficacy, suggesting the 8 mg dose may represent near-maximal practical efficacy for most individuals. Use the dosing calculator to model research preparation volumes for retatrutide at different target concentrations.
All Phase 2 and anticipated Phase 3 clinical studies employ subcutaneous injection as the sole route. The extended half-life conferred by the albumin-binding fatty acid moiety makes once-weekly subcutaneous dosing pharmacokinetically appropriate. Time to maximum plasma concentration (Tmax) following subcutaneous injection is expected to be similar to tirzepatide (8–72 hours), reflecting the slow release from the subcutaneous depot as albumin-bound peptide equilibrates into the systemic circulation.
Intravenous and intramuscular routes have been used in some preclinical mechanistic studies to achieve rapid, defined plasma exposures for pharmacodynamic assessments, but these routes are not relevant to the intended clinical application. No oral formulation has been reported in clinical development. As with all peptide therapeutics of this structural class, retatrutide is not orally bioavailable without specialized delivery technology due to rapid proteolytic degradation in the gastrointestinal tract and poor mucosal absorption of large lipidated peptides.
Once-weekly subcutaneous injection is the only dosing frequency tested in human trials. The pharmacokinetic rationale is identical to tirzepatide: the albumin binding mediated by the C20 fatty acid moiety extends the effective half-life to approximately four to six days, ensuring that plasma concentrations remain well within the therapeutic range throughout the weekly dosing interval without the peaks and troughs that would produce unacceptable side effect variability with shorter-acting compounds.
Steady-state plasma concentrations are expected to be achieved after approximately two to three weekly doses, at which point receptor occupancy becomes relatively stable and both efficacy and tolerability reach their characteristic plateau for a given dose level. In Phase 2 trials, dose escalations were performed every four weeks, a schedule that allows sufficient time for steady-state concentrations to be established at each dose level before assessing tolerability and readiness for escalation. There are no published data on alternate dosing frequencies (biweekly, twice-weekly) for retatrutide in humans.
Retatrutide is not approved for clinical use and is available only through research channels as an investigational or reference standard compound. Lyophilized retatrutide for research reconstitution should be dissolved in sterile water for injection or phosphate-buffered saline (pH 7.0–7.4) at the minimum volume required to achieve the target working concentration, typically 1–5 mg/mL for subcutaneous dosing research applications.
As a lipidated peptide, retatrutide is somewhat more challenging to reconstitute than non-acylated peptides; gentle warming to room temperature and slow trituration (avoid vortexing, which may cause aggregation of the lipid moiety) are generally recommended. Solutions should be inspected visually for clarity and the absence of particulates before use. Storage at 2–8°C after reconstitution, protected from light, with a use-within window of 28 days, follows standard practice for this peptide class. Consult the supplier’s certificate of analysis for validated stability endpoints specific to your preparation conditions.
Preclinical safety studies for retatrutide, as required for IND filing and clinical advancement, included standard rodent and non-rodent toxicology studies. As with all GLP-1R agonist-containing compounds, thyroid C-cell hyperplasia was observed in rodents at pharmacologically active doses, and this class-based finding carries forward to retatrutide’s regulatory labeling strategy. The addition of glucagon receptor agonism raises specific preclinical safety questions not encountered with pure GLP-1R or dual GIP/GLP-1R agonists, particularly regarding hepatic glucose production, cardiac function, and bone metabolism.
Glucagon receptor activation in rodent models at doses above the therapeutic range can cause adverse cardiac effects, including heart rate elevation and, at extreme doses, myocardial oxygen demand imbalance. At Phase 2-relevant doses, no cardiac safety signals were detected in preclinical or clinical studies. Glucagon is known to have catabolic effects on bone in isolated tissue studies, raising theoretical concern for bone density reduction; however, the weight loss achieved with retatrutide, and the associated improvements in mechanical loading of the skeleton, may partially or fully offset any direct GCGR-mediated effects on bone turnover. Dedicated bone density assessments in Phase 3 trials will provide clearer data.
The Phase 2 safety profile of retatrutide was broadly consistent with the incretin agonist class. Gastrointestinal adverse events — nausea, vomiting, diarrhea, constipation — were the most common treatment-emergent events across all active dose groups. Nausea was reported by approximately 40–50% of participants in the highest dose groups during the escalation phase, declining substantially once maintenance dosing was established. Discontinuation rates due to gastrointestinal events were approximately 5–7% in the 8 mg and 12 mg groups, comparable to tirzepatide at equivalent weight-loss doses.
Heart rate increased modestly in Phase 2 participants, averaging approximately 5–8 beats per minute above placebo, a signal also observed with GLP-1R agonists and attributed to both direct receptor-mediated effects on sinoatrial node automaticity and reflex tachycardia secondary to blood pressure reduction. This heart rate effect is of regulatory interest given the glucagon receptor component. No serious cardiac arrhythmias attributable to retatrutide were identified in Phase 2. Hypoglycemia rates were low in the non-diabetic obesity trial, as expected. The NEJM 2023 publication reported no episodes of severe hypoglycemia in the primary cohort.
Retatrutide’s evidence base, while highly promising, is limited primarily to a single Phase 2 randomized controlled trial of 48 weeks’ duration. The long-term safety and efficacy profile, cardiovascular outcomes, and durability of effects are entirely unknown and will only be established through the ongoing Phase 3 program over the next several years. The interaction between glucagon receptor agonism and bone health, renal function, and long-term hepatic function in the context of chronic triple agonist therapy has not been adequately studied in humans.
Additionally, the optimal dose for different populations — people with type 2 diabetes, MASH, CKD, cardiovascular disease — has not been established. The question of whether the maximum studied dose (12 mg) truly represents the top of the efficacy-tolerability curve, or whether higher doses would produce additional benefit with manageable side effects, awaits future investigation. Treatment withdrawal and rebound dynamics, which have major implications for clinical practice guidelines, are completely uncharacterized for retatrutide. Researchers should treat all Phase 2 findings as hypothesis-generating and await Phase 3 confirmatory data before drawing definitive mechanistic or clinical conclusions. The peptide database includes updated research citations as Phase 3 data become available.
Tirzepatide is a dual agonist targeting GLP-1R and GIPR. Retatrutide adds a third receptor target: the glucagon receptor. This additional glucagon receptor activation is the key mechanistic distinction. Glucagon receptor agonism in brown adipose tissue and skeletal muscle promotes thermogenesis and fat oxidation, adding an energy expenditure component to the appetite suppression and insulin secretion amplification already provided by the GLP-1R and GIPR components. In the Phase 2 head-to-period comparison (not a direct head-to-head trial, but comparing results against published tirzepatide data at 48 weeks), retatrutide at 12 mg produced approximately 3–4 percentage points greater weight loss. Whether this magnitude of incremental benefit will be confirmed in prospective head-to-head Phase 3 comparisons remains to be seen.
No. As of early 2026, retatrutide is an investigational compound without regulatory approval in any country. It is available only through clinical trial participation or legitimate research channels. Phase 2 trials have been completed and published, and Phase 3 trials are underway. Eli Lilly has not publicly announced a projected regulatory submission or approval timeline, though the pace of Phase 3 enrollment and the strength of Phase 2 data suggest the compound is on a regulatory fast track. Anyone claiming to sell “approved” retatrutide for clinical use outside of trial settings should be regarded with significant skepticism. Researchers interested in tracking clinical trial progress can use the peptide database for linked trial registry information.
To appreciate the significance, it helps to know the historical context. For decades, the most effective pharmacotherapy for obesity — phentermine-topiramate combination — produced mean weight loss of approximately 8–11% in controlled trials. The arrival of GLP-1R agonists represented a step change: liraglutide 3 mg achieved approximately 8%, and semaglutide 2.4 mg achieved approximately 15% in the STEP 1 trial. Tirzepatide raised the ceiling further to 20.9% in SURMOUNT-1. Retatrutide’s Phase 2 result of 24.2% represents a further advance. More importantly, 26% of participants on the highest dose achieved 30% or greater weight loss — a threshold associated with major cardiovascular, joint, metabolic, and quality-of-life benefits that approaches what bariatric surgery reliably produces. If Phase 3 confirms these findings, retatrutide would become the most effective pharmacological weight-loss therapy ever tested in a large randomized trial.
This is the central pharmacological tension in retatrutide’s design, and the answer in clinical data is: no, not at therapeutic doses, provided appropriate dose ratios of the three receptor agonist components are maintained. Glucagon does raise blood glucose in isolation, primarily by stimulating hepatic glycogenolysis and gluconeogenesis. However, retatrutide’s simultaneous GLP-1R and GIPR activation strongly amplifies glucose-stimulated insulin secretion, which counteracts the hepatic glucose output. Clinical Phase 2 data showed net HbA1c reductions (not increases) in both diabetic and non-diabetic participants, confirming that the incretin receptor component dominates the glycemic equation at the doses studied. The art of designing a functional triple agonist lies precisely in tuning this balance, and medicinal chemists at Eli Lilly spent years optimizing the relative receptor potency ratios to ensure glycemic neutrality or benefit.
The liver fat findings from the Phase 2 trial were extraordinary by any prior benchmark. In participants with elevated hepatic fat at baseline (MRI-PDFF above 5%, mean around 16%), retatrutide at 12 mg weekly reduced liver fat fraction by approximately 81% over 48 weeks — from roughly 16% to below 3%, which is within the normal range. This represents near-complete normalization of liver fat in the majority of affected participants and substantially exceeds what has been reported for any other pharmacotherapy in comparable non-biopsy studies. The mechanistic synergy between GLP-1R-mediated insulin sensitization, GIP-mediated adipose remodeling, and glucagon receptor-driven hepatic fat oxidation is believed to explain this superior hepatic response. Phase 3 trials with liver biopsy endpoints will determine whether this translates to histological MASH resolution and fibrosis regression.
Traditional benchmarks for Roux-en-Y gastric bypass surgery are total body weight loss of 25–35% at one to two years, and for sleeve gastrectomy, approximately 20–25%. The mean 24.2% weight loss seen with retatrutide 12 mg at 48 weeks places it squarely in the sleeve gastrectomy range on a population-average basis, and the 26% of participants achieving 30%+ loss approaches bypass outcomes in the most responsive patients. However, important caveats apply. Surgery produces effects through multiple mechanisms (anatomical restriction, gut hormone remodeling, microbiome changes, altered bile acid metabolism) that extend beyond any single pharmacological pathway. Surgery also does not require ongoing daily or weekly compliance. The rebound dynamics after retatrutide cessation (unstudied as yet) are expected to differ markedly from the more durable effects of irreversible anatomical procedures. Pharmacotherapy and surgery therefore remain complementary tools rather than direct substitutes.
Retatrutide completed Phase 2 trials in obesity and type 2 diabetes with results published in major journals in 2023. Eli Lilly initiated Phase 3 trials — required for regulatory approval — targeting obesity, type 2 diabetes, and potentially MASH as separate indications. Phase 3 trials typically enroll thousands of participants across multiple countries and run for one to three years depending on the primary endpoint. Cardiovascular outcomes trials, if required as a post-approval commitment or pursued proactively as Eli Lilly did with tirzepatide’s SURMOUNT-MMO, would extend the data generation timeline further. Based on the Phase 2 results and the regulatory priority given to obesity and metabolic disease pharmacotherapy, regulatory submissions could realistically occur in 2026–2027 if Phase 3 data are consistent with Phase 2 findings, though no official timeline has been disclosed by Eli Lilly.
Phase 2 data cover only 48 weeks of exposure in a relatively small number of participants, making any definitive long-term safety assessment impossible at this stage. The most important theoretical concerns specific to the glucagon receptor component — beyond those shared with all GLP-1R agonist-containing compounds — include potential effects on cardiac function (heart rate elevation was modest in Phase 2 but warrants monitoring), bone metabolism (glucagon has catabolic bone effects in vitro), and hepatic function in people with pre-existing liver disease. The Phase 2 data did not identify safety signals in any of these areas at the doses studied, but the power to detect rare or delayed adverse events in a 338-person Phase 2 trial is inherently limited. Phase 3 trials with thousands of participants and longer follow-up will provide the safety data set needed for a comprehensive risk-benefit assessment.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.